• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Pharmaceutical Co-crystals: A Review on its Physico-chemical Properties and Role in the Management of Cancer
  • VIEWS 641
  • PDF 170

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v23.1.74

Year: 2024, Volume: 23, Issue: 1, Pages: 1-6

Review Article

Pharmaceutical Co-crystals: A Review on its Physico-chemical Properties and Role in the Management of Cancer

Manoleena Sarkar1, Rajnandan Borah1, Rajat Das1,*, , Pallab Ghosh1, Chandrika Sharma1, Jyochhana Priya Mohanty1

1Department of Pharmacognosy, Himalayan Pharmacy Institute, Majhitar, E. Sikkim, 737136

*Corresponding author email: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Academic and industry researchers are becoming more interested in pharmaceutical cocrystals as they emerge as a new class of solid pharmaceuticals with enhanced physico-chemical features. Pharmaceutical co-crystal formation is a simple method for significantly altering a therapeutic substance's solid-state characteristics namely its solubility and consequently bioavailability. A drug's physico-chemical properties can be adjusted by a cocrystal between an active pharmaceutical ingredient (API) and co-former without altering the drug's molecular structure. Numerous types of co-crystals, nano co-crystals and co-crystal-loaded nanocarriers have shown significant promise in the fight against cancer through enhanced pharmacokinetic capabilities, decreased toxicities and improved physico-chemical properties. In this review the physico-chemical properties of co-crystals along with its impact in management of cancer have been demonstrated.

Keywords

Co-Crystals, Physicochemical, Co-Former, Bioavailability, Nanocarriers

References

  1. Ning Q, Mingzhong L, Walkiria S, Nazneen M, Gary AD, T. Pharmaceutical cocrystals: An overview. International journal of pharmaceutics. 2011;419(1-2). Available from: https://doi.org/10.1016/j.ijpharm.2011.07.037
  2. Chandur VK, Sobhanan A, Shabaraya AR, . Pharmaceutical co-crystals: an overview . 2020. Available from: https://doi.org/10.20959/wjpps202011-17537
  3. Bolla G, Sarma B, Nangia AK. Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs. Chemical Reviews. 2022;122(13):11514–11603. Available from: https://doi.org/10.1021/acs.chemrev.1c00987
  4. Jones W, Motherwell WDS, Trask AV. Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement. MRS Bulletin. 2006;31(11):875–879. Available from: https://doi.org/10.1557/mrs2006.206
  5. Varma NL, Hemalatha M, Sai M, Lakshmi B, Kavitha K, Hima K, et al. A comprehensive review on co-crystals. Indo American Journal of Pharmaceutical Sciences. 2021(06):242–250.
  6. Kumar AR, Saloni J, Kumar D, Lal S, Sharma S. An Overview on Pharmaceutical Co-Crystals. Asian Journal of Pharmaceutical Research and Development. 2019;7(2):39–46. Available from: https://doi.org/10.22270/ajprd.v7i2.483
  8. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. Acta Pharmaceutica Sinica B. 2021;11(8):2537–2564. Available from: https://doi.org/10.1016/j.apsb.2021.03.030
  9. Kumbhar P, Kolekar K, Khot C, Dabhole S, Salawi A, Sabei FY, et al. Co-crystal nanoarchitectonics as an emerging strategy in attenuating cancer: Fundamentals and applications. Journal of Controlled Release. 2023;353:1150–1170. Available from: https://doi.org/10.1016/j.jconrel.2022.12.042
  11. Padrela L, Azevedo EGD, Velaga SP. Powder X-ray diffraction method for the quantification of cocrystals in the crystallization mixture. Drug Development and Industrial Pharmacy. 2012;38(8):923–929. Available from: https://doi.org/10.3109/03639045.2011.633263
  13. Thenge R, Adhao V, Mehetre G, Chopade N, Chinchole P, Popat R, et al. Modification of Physicochemical Properties of Active Pharmaceutical Ingredient by Pharmaceutical Co-Crystals. Drug Formulation Design. 2023. Available from: https://doi.org/10.5772/intechopen.110129
  14. Lin HLL, Zhang GCC, Huang YTT, Lin SYL. An Investigation of Indomethacin–Nicotinamide Cocrystal Formation Induced by Thermal Stress in the Solid or Liquid State. Journal of Pharmaceutical Sciences. 2014;103(8):2386–2395. Available from: https://doi.org/10.1002/jps.24056
  15. Chettri A, Subba A, Singh GP, Bag PP. Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy. Journal of Pharmacy and Pharmacology. 2024;76(1):1–12. Available from: https://doi.org/10.1093/jpp/rgad097
  16. Novais MVM, Gomes ER, Miranda MC, Silva JO, Gomes DA, Braga FC, et al. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines. Biomedicine & Pharmacotherapy. 2021;136:111123. Available from: https://doi.org/10.1016/j.biopha.2020.111123
  17. Cooper GM, Hausman RE. The Development and Causes of Cancer. In: The Cell: A Molecular Approach. Sinauer Associates Inc. 2000.
  19. Ray E, Vaghasiya K, Sharma A, Shukla R, Khan R, Kumar A, et al. Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy. AAPS PharmSciTech. 2020;21(7). Available from: https://doi.org/10.1208/s12249-020-01803-z
  21. Sinthiya A, Koperuncholan M. Synthesis and characterization of l-amino acid doped 2-aminopyridine co-crystals for anti-cancer activity. Life Science Informatics Publications-Research Journal of Life Sciences. 2019;5(2):754–762. Available from: http://www.rjlbpcs.com/article-pdf-downloads/2019/26/585.pdf
  22. Saha R, Sengupta S, Dey SK, Steele IM, Bhattacharyya A, Biswas S, et al. A pharmaceutical cocrystal with potential anticancer activity. RSC Adv.. 2014;4(90):49070–49078. Available from: https://pubs.rsc.org/en/content/articlelanding/2014/ra/c4ra03207a
  23. Urooj I, Choudhary M, Sammer Y. Synthesis of co-crystals of anti-cancer nandrolone as a potential leads towards treatment of cancer. Journal of Molecular Structure. 2021. Available from: https://doi.org/10.1016/j.molstruc.2020.128981
  24. Nadzri NI, Sabri NH, Lee VS, Halim SNA. 5-Fluorouracil Co-crystals and Their Potential Anti-cancer Activities Calculated by Molecular Docking Studies. Journal of Chemical Crystallography. 2016;46(3):144–154. Available from: https://doi.org/10.1007/s10870-016-0638-y
  25. He-Mei Y, Bi-Jian NW, Zhou BJ, Hong MH, Zhu B, Qi MH, et al. Slow-release drug-drug cocrystals of oxaliplatin with flavonoids: delaying hydrolysis and reducing toxicity. 2020;21:75–85.
  26. Kusuma, Kanakaraju K, Lavanya V, Nangia A. Temozolomide Cocrystals Exhibit Drug Sensitivity in Glioblastoma Cells. Proceedings of the National Academy of Sciences, India Section A: Physical Sciences. 2014;84(2):321–330. Available from: https://doi.org/10.1007/s40010-014-0142-8
  27. Shaik A, Bhagwat PU, Palanisamy P, Chhabria D, Dubey P, Kirubakaran S, et al. Novel pharmaceutical co-crystals of gefitinib: synthesis, dissolution, cytotoxicity, and theoretical studies. CrystEngComm. 2023;25(17):2570–2581. Available from: https://doi.org/10.1039/D3CE00056G
  28. Peddy V, Jennifer A, Mc JAM, Bis MJ, Zaworotko. Pharmaceutical co-crystals. Journal of pharmaceutical sciences Mar. 2006;95(3):499–516. Available from: https://pubmed.ncbi.nlm.nih.gov/16444755/

Copyright

© 2024 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 22 May 2024

Year: 2024, Volume: 23, Issue: 1


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.